Abstract-Abnormal nocturnal blood pressure (BP) dipping status may be partly determined by nocturnal sympathetic activity. We studied the effect of nighttime dosing of an ␣ 1 -adrenergic blocker, doxazosin, on the BP dipping status of 118 hypertensives, all of whom underwent 24-hour ambulatory BP monitoring before and after treatment. The mean nighttime/daytime ratio of systolic BP was increased (0.91 after therapy versus 0.89 at baseline, PϽ0.05). The patients were initially divided into 4 groups on the basis of their dipping status at the baseline assessment: 18 (15%) were extreme dippers, with a nighttime systolic BP fall of at least 20% of daytime BP; 46 (39%) were dippers (fall between 10% and 20%); 48 (41%) were nondippers (fall between 0% and 10%); and 6 (5%) were risers (nocturnal increase of systolic BP). A shift in dipping status toward less nocturnal BP dipping was observed after doxazosin therapy (PϽ0.05). Dipping status was determined by nighttime more than by daytime BP, and this was not explained by differences in the number of daytime and nighttime readings. The effects of doxazosin on the mean nocturnal systolic BP changes were an increase of 4.3 mm Hg in extreme dippers and decreases of 0.7 mm Hg in dippers, 12 mm Hg in nondippers, and 18 mm Hg in risers; the reduction was only significant in the latter 2 groups (both PϽ0.01). To estimate the effects of regression to the mean on the changes in dipping status, we also defined dipping status with the average of the BPs before and after doxazosin and found no difference in the degree of nighttime BP reduction among each group. The reduction of daytime BP was now significantly greater in the subgroups with less dipping: 6.4 mm Hg for extreme dippers and 16 mm Hg for risers (PϽ0.05). In conclusion, nighttime dosing with doxazosin markedly affects the nocturnal BP dipping status of hypertensives, but the apparently greater reduction in nighttime pressure in nondippers and risers may be, at least partly, due to the effect of regression to the mean. The most important determinants of the effect of doxazosin were the absolute BP levels, both day and night, rather than dipping status per se. (Hypertension. 2000;35:787-794.) Key word: blood pressure monitoring Ⅲ adrenergic receptor blocking Ⅲ circadian rhythm Ⅲ prospective studies
O ne of the most interesting features revealed by ambulatory blood pressure (BP) monitoring (ABPM) is the diurnal variation of BP. 1 Most normotensive and hypertensive individuals show a decrease of BP of Ϸ10% during the night (the so-called dipping pattern), but there are others in whom the BP decrease may be reduced (nondippers) [2] [3] [4] [5] [6] or exaggerated (extreme dippers). 7, 8 These different patterns are increasingly thought to be of clinical relevance because there is evidence from a large prospective study 6 that hypertensive patients who are nondippers are at greater risk of cardiovascular morbidity than dippers. There is also evidence that extreme dippers are at increased risk of ischemic stroke, possibly as a result of the excessive nocturnal BP fall. 9 Another clinically relevant group is patients with renal failure, in whom nondipping is associated with microalbuminuria (an early marker of renal damage). 4 One prospective study 4 has found that nondipping is an independent risk factor for progression of renal disease. Thus, it is reasonable to suppose that deviations from the normal dipping pattern in either direction can have pathological significance, although for different reasons. Nondippers experience a greater "BP load" over 24 hours than dippers with the same daytime BP and, hence, may be more likely to develop target organ damage. On the other hand, extreme dippers might be more susceptible to ischemic episodes that result from low BP, especially in high-risk hypertensive patients with predisposing arterial stenosis (eg, elderly hypertensives 7 and patients with carotid artery disease 10 or coronary artery disease 8 ) when antihypertensive therapy lowers nocturnal BP further.
The mechanisms of dipping are complex. Although both demographic factors (eg, older age and black race) and medical conditions (renal disease, diabetes, Cushing disease, etc) are associated with nondipping, lifestyle and behavioral factors are also important. [11] [12] [13] Thus, both the level of physical activity during the day and the duration and quality of sleep during the night will influence the observed diurnal BP changes. 14 The underlying physiological mechanisms are also likely to be complex. The nocturnal decrease of BP is in part determined by changes in sympathetic nerve activity. Thus both plasma and urine catecholamines are lower during the night than during the day, 15 and direct recordings from muscle sympathetic nerves have also shown a decreased level of activity during slow-wave (but not REM) sleep. 16 In previous studies that assessed heart rate variability, abnormal dipping status (nondippers and extreme dippers) was also partly determined by the abnormal variation of sympathovagal balance during the sleep and awake periods. 17, 18 Recently, there have been several papers on the differential effects of antihypertensive medications on the diurnal variation of ambulatory BP (ABP) levels in hypertensives with different nocturnal dipping status. 19 -25 Doxazosin, an ␣ 1 -adrenergic blocker, may suppress the ␣ 1 -adrenergicdependent BP level selectively, suppressing nighttime BP levels only in hypertensive nondippers but not in hypertensive dippers. 19 However, there is no report of nighttime dosing of doxazosin on nocturnal BP in extreme dippers, and most previous studies have not evaluated the possible effects of regression to the mean. In this substudy of the Hypertension and Lipid Trial (HALT), 26, 27 we have investigated the effect of nighttime dosing of doxazosin on the BP dipping status of hypertensive subgroups with different nocturnal BP dipping.
Methods

Patient Selection
The HALT study was an open-label study of the effects of doxazosin on BP and plasma lipids and included 851 patients at 141 centers throughout the United States. Thirty-nine of these sites were equipped to perform ABPM, and 118 hypertensive patients who were either untreated or off medication for Ն2 weeks (41 men and 77 women) with meanϮSD age of 54Ϯ10 years were included in the substudy of ABPM. The entry BP criterion was a seated diastolic BP (DBP) between 96 and 110 mm Hg at each of the last 2 weekly visits. To be included in the study, patients had to be Ͼ35 years of age, have a diagnosis of essential hypertension, and have no history of other significant medical disorders, including drug or alcohol misuse.
Study Design
Each patient was studied for a maximum of 13 weeks, with a titration period of Յ5 weeks, and 8 weeks of maintenance. After the baseline evaluation was completed, patients were started on 1 mg doxazosin daily, which was taken at bedtime. The dose was doubled at weekly intervals until either the average seated DBP was Ͻ90 mm Hg and had fallen by Ն10 mm Hg from the baseline level on each of 2 consecutive visits, a maximum daily dose of 16 mg doxazosin had been reached, or side effects precluded a further dose increase. After the titration phase, there was a maintenance phase of 8 weeks on the same dose of doxazosin. All patients signed an informed consent statement approved by the local Institutional Review Board.
ABPM and Patient Classification
ABPM was performed twice with a Spacelabs model 90202 recorder, at the end of the drug-free baseline period and at the end of the maintenance period, as described previously. 26, 27 The monitor was programmed to take readings every 15 minutes during typical waking hours (6 AM to 10 PM) and every 30 minutes during the night (10 PM to 6 AM). At least 6 readings were required for an acceptable nighttime recording, and 30 readings were required for an acceptable daytime recording. For the present analyses, nighttime parameters (BP and pulse rate) were defined by the averages from midnight to 6 AM, and daytime parameters were defined by the averages from 8 AM to 8 PM. The night/day ratios of each parameter were calculated. Nocturnal BP fall was calculated as 1Ϫthe night/day ratio of systolic BP (SBP) and expressed as a percentage. Patients were subclassified into the following 4 dipping groups on the basis of the baseline nocturnal BP fall: extreme dippers, with a nocturnal BP fall of 20% or more; dippers, with a fall between 10% and 20%; non-dippers, with a fall between 0% and 10%; and risers, with a nocturnal increase of SBP. To estimate the effects of regression to the mean on the changes in dipping status, we also defined dipping status using the average of baseline BP and BP after doxazosin.
Statistical Analysis
Changes in BP or pulse rate from the baseline values were analyzed statistically with paired t tests for each of the 4 subgroups. The between-subgroup comparisons were tested statistically with Tukey's honestly significant difference test after 1-way ANOVA. The linear contrast among the 4 subgroups (from extreme dippers to risers) was also tested. The change in dipping status after doxazosin therapy was tested with the McNemar test, and Pearson's correlation coefficients were calculated. The criterion for determining statistical significance was PϽ0.05. The results are given as the mean (SD).
Results
The mean night/day SBP ratio was highly correlated between assessments (rϭ0.497, PϽ0.001). However, this ratio increased after treatment with doxazosin (from 0.89 at baseline to 0.91 after therapy, PϽ0.05). At the baseline BP assessment (Table 1) , there were 18 (15%) extreme dippers, 46 (39%) dippers, 48 (41%) nondippers, and 6 (5%) risers. There were no significant differences in the daytime BP levels among groups, but the mean nighttime SBP levels varied substantially; from 118 mm Hg in the extreme dippers to 153 mm Hg in the risers, with marked differences between each group (PϽ0.01, except for the difference between nondippers and risers). Thus, dipping status appeared to be determined much more by the nighttime than by the daytime BP. After doxazosin therapy, the mean nocturnal SBP increased by 4.3 mm Hg in the extreme dippers but decreased in the other groups (by 0.7 mm Hg in the dippers, 12 mm Hg in the non-dippers, and 18 mm Hg in the risers). These changes were statistically significant only in the latter 2 groups (PϽ0.05). In contrast, there was a substantial drop in daytime SBP after doxazosin therapy that did not vary by group. The lack of significance for the change of daytime SBP (Ϫ11 mm Hg) in the risers can be attributed to the small number of patients in this group. The pattern of change in DBP in each group was similar to that of SBP. There were no group differences in baseline pulse rates nor were there any significant changes after doxazosin therapy. Table 2 shows the changes in dipping status after doxazosin therapy. Fifty-six percent (nϭ10) of the 18 extreme dippers changed to dippers (nϭ4), nondippers (nϭ5), or risers (nϭ1) after therapy. The overall numbers of dippers and nondippers were not significantly different after therapy, whereas the number of risers increased (from 6 to 16). Thus, there was an overall shift toward less nocturnal BP dipping after doxazosin therapy (PϽ0.05, by McNemar's test). Figure 1 shows the relationship between the baseline daytime and nighttime BP levels and the changes after doxazosin therapy for the whole group. Almost the same regression lines were obtained for daytime and nighttime SBP ( Figure 1 ). Figure 1 also indicates that doxazosin has only a BP lowering effect when the baseline BP exceeds Ϸ125 mm Hg, regardless of whether this is during the daytime or nighttime. Analysis of covariance revealed that the relationship between daytime BP at baseline and the change in daytime BP did not vary (neither the slopes nor the intercepts) significantly across the 4 dipping status groups. The same was true for nighttime BP. Figure 2 shows the same data plotted according to the average levels and changes in each of the 4 subgroups. It demonstrates a cluster of points corresponding to the daytime BPs and a strong inverse relationship between the baseline level and the doxazosin- induced change for the nighttime BPs, for which the correlation was Ϫ0.995. Taken together, these 2 figures show that the effects of doxazosin on daytime and nighttime BPs are generally similar and that the apparently different effects in the subgroups are determined by the fact that the classification of baseline dipping status is almost exclusively the result of differences in nighttime BPs.
It is possible that the reason the dipping status was determined more by the nighttime than by the daytime BPs is that the smaller number of nighttime readings make each individual's average nighttime level less reliable than his/her average daytime level. To test the effect of the number of BP measurements on dipping status, we randomly selected 10 readings from the daytime BP measurements (thus giving the same number of readings as during the night) and computed the correlations between dipping status and daytime SBP calculated with (a) all of the readings and (b) the 10 daytime readings (Table 3) . Dipping calculated with all of the daytime readings was significantly related to the nighttime SBP (rϭϪ0.689, PϽ0.001) but not to the daytime SBP (rϭ0.112, not significant) in the baseline data, the data after doxazosin therapy, and the changes after doxazosin therapy. The effect of using only 10 daytime readings was to reduce the differences between the daytime and nighttime correlations but not to eliminate them. Thus for the baseline data, the correlation with the nighttime SBP was reduced from Ϫ0.689 to Ϫ0.645 (PϽ0.00l), whereas the correlation with daytime SBP increased slightly (from 0.122 to 0.191, PϽ0.05). The effects on the posttreatment data and on the changes after doxazosin were more marked. Nonetheless, the differential effect of the daytime and nighttime readings on dipping status cannot simply be ascribed to the larger number of readings taken during the day; in this sample, nighttime BP is a stronger predictor of dipping than daytime BP.
To explore the possible effects of regression to the mean on the estimated changes in daytime and nighttime BPs after treatment, we also defined dipping status using the average of the baseline BP and the BP after doxazosin. With this definition, there were no differences in the degree of nighttime BP reduction among groups (Table 4) . However, the reduction of daytime SBP was now significantly greater in those subgroups with less dipping: 6.4 mm Hg in the extreme 
Discussion
Nighttime dosing with doxazosin therapy reduces both daytime and nighttime SBP and DBP in hypertensives and appears to also affect their nocturnal dipping status. The overall effect was an increase of the night/day ratio, and a shift in dipping status toward less nocturnal BP dipping. This, of course, confirms our earlier analysis of the same data in which we reported that doxazosin lowers daytime BP more than nighttime BP. 26 The effects of doxazosin in hypertensives who differ according to their dipping status are of interest because there is increasing evidence that the nighttime BP may have pathological and prognostic significance that is independent of the daytime BP. 6 At one extreme, it might be beneficial to selectively lower the nighttime BP in nondipping patients with albuminuria and renal disease, whereas at the other extreme, further reduction of nighttime pressure in extreme dippers might exacerbate the development of cerebral ischemic lesions.
A weakness of this study is that we did not have placebo controls. A potential problem that must be addressed in an analysis of the effects of antihypertensive drugs according to dipper status without placebo controls is the reproducibility of the dipping status, which might be affected by regression to the mean. When subjects are initially classified according to whether the difference between daytime and nighttime BP is either large or small, they are likely to show less extreme differences on repeat testing. Thus, a proportion of both extreme dippers and nondippers are expected to be classified as dippers on repeat testing. If the second evaluation is made after administering a drug, the apparent effect of the drug will be to produce a greater fall of nocturnal BP in the nondippers than in the dippers (as we observed). The best way to exclude this effect is to administer placebo pills to a control group, 23, 24 but this may be difficult to perform in the clinical practice setting. Recently, after the recognition of the potential clinical significance of differences in dipping patterns, there have been several studies of the effects of antihypertensive drugs in hypertensive subjects who differ in their nocturnal BP dipping status. With 2 exceptions, 23,24 these previous studies 19 -22,25 did not have a placebo control condition. However, the results obtained from these studies have been consistent, indicating that nocturnal BP is decreased by a greater extent in nondipper hypertensives than in dipper hypertensives after treatment with a wide variety of antihypertensive agents (calcium antagonists, angiotensin-converting enzyme inhibitors, and ␣ 1 -adrenergic blockers). 19 -24 Because dipping status is determined by both sleep and awake BPs, it might be expected that the 2 determinants would have equal weight. However, in our data, there were no differences among groups in the awake BP levels such that differences in dipping status were determined almost exclusively by differences in nocturnal BP level. Exactly the same thing was shown by White et al 21 in their analysis of the effects of extended-release verapamil: the awake BP of the dippers and nondippers were 156/97 and 157/99 mm Hg, respectively, while the corresponding sleep BPs were 133/78 and 152/94 mm Hg, respectively. A probable explanation for this is statistical rather than biological. The duration of the sleep period is less than the duration of the waking period, thus the reliability of the estimate of the average sleep BP level will also be less. This will be particularly true of studies such as ours in which the frequency of readings was less during the night than during the day (in the White et al study it was the same throughout). The comparative unreliability of the sleep readings would also explain the reason White et al found that the administration of a placebo apparently lowered the nighttime SBP/DBP of nondippers by 5/3 mm Hg and raised it in dippers by 3/3 mm Hg, without any effect on the daytime BPs of either group. However, when we reanalyzed the data with the same number of awake and sleep readings, we found that this only partially removed the greater influence of nighttime versus daytime readings on dipping status. Another explanation may be selection bias that resulted from the recruitment criteria of drug treatment studies in hypertensive patients. In this study, as in others, patients were selected according to their clinic BP, which is more closely related to the daytime than to the nighttime BP. Thus, the range of daytime BP will tend to be narrow, whereas the nighttime BP will range more widely. This is precisely what was observed in this HALT study (daytime SDϭ13.0 mm Hg; nighttime SDϭ15.8 mm Hg). (18) 144 (11) 141 (12) 139 ( #PϽ0.05, ##PϽ0.01, ###PϽ0.001 using paired t-test for the change between baseline value and that after the doxazosin therapy.
To exclude the effect of regression to the mean, we also classified patients into the 4 dipping status groups with the average of their BP values before and after doxazosin therapy. With this classification, we found no differences in the degree of nighttime SBP reduction among groups. The reduction of daytime SBP was now significantly greater in the subgroups with less dipping: 6 mm Hg for extreme dippers and 16 mm Hg for risers. The reduction of nighttime BPs also tended to be greater in the subgroups with less dipping. Thus, the apparently greater reduction in nighttime BP in nondippers and risers may be largely because of the effect of regression to the mean. However, if we subtract the estimated effect of regression to the mean derived from the White et al study (3/3 mm Hg in nondippers and risers, and Ϫ5/Ϫ3 mm Hg in dippers and extreme dippers), there appears still to be a differential effect of doxazosin on nocturnal BP according to dipper status. Thus, we observed a differential effect of doxazosin between these 2 aggregate groups of 13.4 mm Hg on SBP. If we subtract 8 mm Hg from this (to allow for regression to the mean), there is still a difference of 5.4 mm Hg.
The similarity of the effects of treatment on daytime and nighttime BP as a function of the baseline level shown in Figure 1 suggests that the most important determinant of the effect is the level of BP rather than the dipping status per se. Thus in extreme dippers with marked nighttime BP fall, the dipping was less after doxazosin therapy, while at the other extreme, in risers and nondippers, it was increased. The effects of doxazosin therapy on dipping status suggest that ␣-adrenergic action contributes to the diurnal BP variation in hypertensive patients. Two studies in rats have investigated the effects of different antihypertensive agents on the diurnal BP variation. One used captopril, clonidine, hydralazine, metoprolol, and prazosin, 28 and found that hydralazine and captopril had little effect, whereas clonidine and metoprolol produced a minor flattening of the BP rhythm. In contrast, ␣-blockade with prazosin completely eliminated the diurnal BP changes. The second study 29 used metoprolol with atropine (to produce cardiac autonomic blockade), hexamethonium, and prazosin. Blockade of the heart had no effect on BP, whereas both ␣-and ganglionic-blockade eliminated the diurnal BP changes. These data suggest that ␣-adrenergic tone plays an important role in the diurnal changes of BP, at least in the rat. Studies in humans are less clear-cut. In a previous analysis of the HALT data, in which doxazosin was given at night to hypertensive patients, we found that the peak BP lowering effect was during the morning hours, with relatively little effect on nighttime BP. 26 This would not be expected from the pharmacodynamics of the drug, which would have predicted a greater effect during the night, but is consistent with other data that shows that ␣-adrenergic tone is greater in the morning than in the evening. A second study, by Ebata et al, 19 compared the effects of doxazosin given twice daily in 15 dippers and 12 nondippers and found that daytime BP was reduced in both groups. However, the nighttime BP was lowered in nondippers but not in dippers. This can be explained by assuming that ␣-adrenergic tone falls during the night in dippers but remains high in nondippers.
The effect of antihypertensive drugs on the diurnal BP variation depends not only on the mechanism of action of the drugs but also on the time of administration and the pharmacokinetics and pharmacodymamics. Thus, when doxazosin is given in the morning, its limited duration of action may result in its having less effect on the nocturnal BP. Nighttime dosing of doxazosin suppresses the morning BP surge (largely dependent on ␣-adrenergic tone). 26 Thus, nighttime dosing might be ideal in hypertensive patients with a nondipping pattern of nocturnal BP or in those having a marked morning BP rise.
In our recent Japanese study using brain MRI, silent cerebrovascular disease was more advanced in hypertensive elderly extreme dippers compared with dippers. 7 This raises the possibility that excessive BP reduction by antihypertensive therapy might advance nocturnal hypoperfusion of cerebral circulation and lead to clinically overt stroke or vascular dementia, especially in high-risk hypertensive patients. The marked nocturnal decrease in the low-frequency power/highfrequency power ratio obtained from the power spectral analysis of heart rate variability (a crude indirect indicator of sympathetic activity) observed in hypertensive extreme dippers suggests that nocturnal BP in these patients may be attributed to a lower level of sympathetic activity compared with other dipping statuses. 17 In addition, the orthostatic BP increase found in hypertensive extreme dippers 30 suggests enhanced vascular reactivity including ␣-adrenergic dominant sympathetic activation or postsynaptic vascular reactivity, such that the exaggerated day/night BP difference may be, at least in part, caused by the effects of posture rather than of sleep. Thus, we speculated that doxazosin decreases daytime BP by suppressing this hyperreactivity, without affecting the (already low) nighttime BP, and hence improves the excessive nocturnal dipping, as demonstrated in 1 typical hypertensive extreme dipper with orthostatic BP increase. 31 In the present study, 56% of extreme dippers changed their dipping status to dippers, nondippers, or risers. This might protect against nocturnal ischemic cardiovascular events and vascular dementia in extreme dippers.
The therapeutic significance of the differential effects of antihypertensive treatment according to dipper status remains uncertain. Although, as discussed above, there is evidence that the extreme dipping pattern may lead to nocturnal ischemia, there is also evidence that nondippers are at greater risk for cardiovascular morbidity than dippers, both for cardiovascular events 6 and for progression of renal disease. 4 Thus, at the present time it is reasonable to suppose that the normal dipping pattern is optimal from a prognostic point of view, and hence that it would be appropriate to use antihypertensive therapy to lower nocturnal BP in nondippers but not in extreme dippers. This is exactly what we observed with doxazosin.
